Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

Smith’s activist challenge got off to a shambolic ... Smith then accused Pfizer of threatening the pair with legal action to get the former executives to change their tune.

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

Court revives lawsuit against Pfizer's diversity fellowship Group ... it issued last year holding the organization lacked legal standing to challenge the drugmaker's program in court.

Pfizer defended the initiative ... this complaint fits a larger wave of legal challenges to diversity programs.

Pfizer's historical legal issues and lobbying activities could lead to RICO charges if RFK Jr. uncovers evidence of fraudulent practices. Despite potential risks, Pfizer's low P/E ratio and robust ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

Amid reports that the pharma industry is preparing a legal challenge to drug price negotiation measures in the Inflation Reduction Act, Pfizer CEO Albert Bourla blasted the plan, calling it ...

David Risinger has given his Hold rating due to a combination of factors surrounding Pfizer’s current financial ... stems from projected revenue growth challenges over the next five years ...